Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16787. [Epub ahead of print]

TIAM1 variants improve clinical outcome in neuroblastoma.

Author information

1
Laboratory of Cellular and Molecular Biology, Instituto de Investigación Sanitaria La Fe, Spain.
2
Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Spain.
3
Precision Oncology Unit, Instituto de Investigación Sanitaria La Fe, Spain.
4
Biostatistics Unit, Instituto de Investigación Sanitaria La Fe, Spain.
5
Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, Leioa, Spain.
6
Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
7
IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

Abstract

Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer. Neuroblastoma is a tumor of the peripheral sympathetic nervous system for which only a few driver alterations have been described including MYCN amplification and ALK mutations. We assessed 106 primary neuroblastoma tumors by next generation sequencing using a customized amplicon-based gene panel. Our results reveal that genetic variants in TIAM1 gene associate with better clinical outcome, suggesting a role for these TIAM1 variants in preventing progression of this disease. The detected variants are located within the different domains of TIAM1 that signal to the upstream regulator RAS and downstream effector molecules MYC and RAC, which are all implicated in neuroblastoma etiology and progression. Clinical outcome was improved in tumors where a TIAM1 variant was present concomitantly with either ALK mutation or MYCN amplification. Given the function of these signaling molecules in cell survival, proliferation, differentiation and neurite outgrowth, our data suggest that the TIAM1-mediated network is essential to neuroblastoma and thus, inhibiting TIAM1 reflects a rational strategy for improving therapy efficacy in neuroblastoma.

KEYWORDS:

TIAM1; neuroblastoma; next generation sequencing; signaling networks

PMID:
28423360
DOI:
10.18632/oncotarget.16787
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Impact Journals, LLC
    Loading ...
    Support Center